Skip to main content
OpenTrials
Completed

NCT Number: NCT05878327

Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia

A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Livedoid Vasculitis Behavior Cardiovascular Diseases Embolism and Thrombosis Hematologic Diseases Hemic and Lymphatic Diseases Livedoid Vasculopathy Skin Diseases Skin Diseases, Vascular Skin and Connective Tissue Diseases Smoking Thrombophilia Thrombosis Vascular Diseases

Age range

10 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University hospital of Basel, Basel, Switzerland

Loading trial locations.

About this study

A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. The presence of Livedoid vasculopathy must be confirmed by a histologic specimen. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia. The presence of a history of smoking and thrombophilia is compared to the general Swiss population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • History of livedoid vasculopathy

Exclusion criteria

  • Diagnosis was not proved by biopsy specimen
  • A different reason than livedoid vasculopathy has been found for the symptoms of the patient
  • No informed consent by the patient

Treatment and study plan

Thrombophilia screening

Other

No intervention. Blood is drawn for analysis.

Primary outcomes

  1. Smoking history: Patients will be asked if they currently smoke or if they are former smokers. If one of both items is yes, it means a positive answer.

    Time frame: 22 months

    The primary endpoint is the comparison of a positive smoking history and other cardiovascular risk factors of patients with livedoid vasculopathy with the Swiss general population.

Secondary outcomes

  1. Thrombophilia screening: the following parameters will be determined in every participant: Factor V Leiden, Prothrombin 20210; Protein C, Protein S, Antithrombin III, Beta 2 Glykoprotein 1, Lupus Antikoagulans

    Time frame: 22 months

    The secondary endpoint is the search for thrombophilia in patients with livedoid vasculopathy.

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
May 26, 2023
Registry last updated
May 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.